Nasdaq Cccc News Today

C4 Therapeutics (NASDAQ:CCCC – Get Free Report)‘s stock had its “buy” rating reissued by Stifel Nicolaus in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $13.00 target price on the stock, up from their previous target price of $12.00. Stifel Nicolaus’ target price would suggest a potential […]

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have been given an average rating of “Hold” by the seven research firms that are presently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year […]

C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) – Equities researchers at Brookline Capital Management issued their FY2028 earnings estimates for shares of C4 Therapeutics in a research note issued to investors on Tuesday, January 9th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of $47.11 for the year. […]

C4 Therapeutics (NASDAQ:CCCC – Get Free Report) and ZIVO Bioscience (NASDAQ:ZIVO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation. Risk and Volatility C4 Therapeutics has a […]

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) was the target of a large growth in short interest in December. As of December 15th, there was short interest totalling 8,100,000 shares, a growth of 330.9% from the November 30th total of 1,880,000 shares. Based on an average daily volume of 11,739,900 shares, the days-to-cover ratio […]

C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) has received an average rating of “Hold” from the seven analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and two have assigned a buy recommendation to the company. The average […]

TCG Crossover Management LLC boosted its holdings in C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) by 2.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,276,574 shares of the company’s stock after buying an additional 26,574 shares during the period. C4 Therapeutics […]

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have been given an average recommendation of “Hold” by the seven analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating […]

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have been given an average rating of “Hold” by the seven ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating […]

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) have earned a consensus rating of “Reduce” from the six research firms that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and one has given a buy recommendation to the […]